China Challenges the West in Stem-Cell Research
By Susan Brown,
The Chronicle of Higher Education
| 04. 10. 2007
In 1983, Sheng Huizhen did what many of China's brightest students do: She left to pursue research opportunities unavailable to her at home, first in Australia and then in the United States. Sixteen years later, in search of greater scientific freedom, she migrated again. This time she headed back to China. As a researcher who studies embryonic stem cells, Ms. Sheng found the climate in the United States limiting. Although she landed a postdoctoral fellowship at the National Institutes of Health, where she worked her way up to a permanent staff position, federal policy at the time barred her from using human embryos or the cells derived from them.
China, however, embraced Ms. Sheng's work. The city of Shanghai in 1999 offered her $875,000 to set up a new center at her alma mater, Shanghai Jiao Tong University, to study embryonic stem cells. She now directs a group of more than 50 people who are working on several lines of research, seeking to make cells useful for treating disease.
Restrictive policies and a frosty cultural climate in the United States...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...